Rash News and Research

RSS

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children.

3 Jun 2014

Patients with advanced colorectal cancer respond well to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.

2 Jun 2014

VA says some vets may get care at private facilities

As the agency seeks to increase its ability to provide services, Secretary Eric Shinseki says when patients will get more access to private clinics and hospitals in areas where the department's services are limited.

28 May 2014

Viewpoints: It's past time to move on VA's problems; administration should report new health law numbers

When America sends men and women to fight, it owes them an enduring debt, starting with competent and timely health care and disability benefits when they leave active duty. President Obama expressed outrage on Wednesday at recent charges of wrongdoing in the Department of Veterans Affairs' health care system.

23 May 2014

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age.

22 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed used in combination with erlotinib may have clinical advantage over single-agent pemetrexed when used as a second-line treatment in patients with non-squamous non-small-cell lung cancer, researchers report.

20 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Wake Forest Baptist offers ways to minimize risks of motorcycle accidents

Riding a motorcycle, like most thrilling activities, comes with its own set of dangers. The Emergency Department at Wake Forest Baptist Medical Center alone treated 166 motorcycle-related cases during fiscal year 2013. Fifteen of those patients died from their injuries.

13 May 2014

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

12 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

College graduation is a time to reassess health insurance

College seniors need to add one item to their "to-do" list as graduation approaches: check out their insurance options, the Los Angeles Times reports. Also, KHN examines California Latinos' interest in getting health care in Mexico--even if they have purchased U.S. insurance.

6 May 2014

First Edition: May 5, 2014

Today's headlines include reports about how President Barack Obama poked fun at the health law during his White House Correspondents' Dinner speech.

5 May 2014

Scientists lay groundwork for understanding immune responses in Lyme disease patients

A team of scientists led by Johns Hopkins and Stanford University researchers has laid the groundwork for understanding how variations in immune responses to Lyme disease can contribute to the many different outcomes of this bacterial infection seen in individual patients. A report on the work appears online April 16 in PLOS One.

21 Apr 2014

Patients' risk of stroke increases following shingles, but antiviral drugs appear to offer protection

Patients' risk of stroke significantly increased following the first signs of shingles, but antiviral drugs appeared to offer some protection, according to a new study in Clinical Infectious Diseases, now available online.

3 Apr 2014

Humans appear to develop immunity against strain-specific Lyme disease that lasts for years

Lyme disease, if not treated promptly with antibiotics, can become a lingering problem for those infected. But a new study led by researchers from the University of Pennsylvania has some brighter news: Once infected with a particular strain of the disease-causing bacteria, humans appear to develop immunity against that strain that can last six to nine years.